Our team has led a series of seminal studies exploring sinonasal disease in children with cystic fibrosis (CF), particularly focusing on how modulator therapy with elexcaftor-texacaftor-ivacaftor (ELX/TEZ/IVA) affects upper airway outcomes.
Beginning with early observational studies, we demonstrated that ELX/TEZ/IVA not only improves pulmonary function, but it also significantly reduces sinonasal symptom burden in children and adolescents (PMID: 34709729) (PMID: 35300931). Our more recent work confirmed these outcomes in younger pediatric groups, establishing a broader role for sinonasal symptom monitoring in CF management (PMID: 37837613) (PMID: 40024881). These studies are among the first to characterize how systemic therapies modulate upper airway disease, expanding the scope of ENT involvement in CF care.
Other Links
- View webinars
The Eye & Ear Foundation hosts Otolaryngology live webinars monthly. Click here to register for future webinars.